• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

益生菌可能通过恢复肠道微生物群落结构和改善肠道内毒素血症来延缓非酒精性脂肪性肝病的进展。

Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.

机构信息

Department of Laboratory, The Second Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.

Department of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.

出版信息

Sci Rep. 2017 Mar 28;7:45176. doi: 10.1038/srep45176.

DOI:10.1038/srep45176
PMID:28349964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5368635/
Abstract

Gut-derived bacterial lipopolysaccharide (LPS) and subsequent hepatic toll-like receptor 4 (TLR4) activation have been recognized to be involved in the onset of diet-induced nonalcoholic fatty liver disease (NAFLD), but little is known about the variation of LPS and TLR4 during the progression of NAFLD. Probiotics were able to inhibit proliferation of harmful bacteria and improve gastrointestinal barrier function. However, it's unclear whether LPS/TLR4 is involved in the protection effect of probiotics on NAFLD. In this study, we described characteristic of gut microbiota structure in the progression of NAFLD, and we also analyzed the relationship between gut microbiota and LPS/TLR4 in this process. Furthermore, we applied probiotics intervention to investigate the effect of probiotics on gut flora structure, intestinal integrity, serum LPS, liver TLR4 and liver pathology. Our results showed that serum LPS and liver TLR4 were highly increased during progression of NAFLD, with gut flora diversity and gut mircobiological colonization resistance (B/E) declining. Furthermore, probiotics could improve gut microbiota structure and liver pathology. Probiotics could also downregulate serum LPS and liver TLR4. Our results suggested that both gut flora alteration and endotoxemia may be involved in the progression of NAFLD. Probiotics may delay the progression of NAFLD via LPS/TLR4 signaling.

摘要

肠道来源的细菌脂多糖(LPS)和随后的肝脏 toll 样受体 4(TLR4)激活被认为与饮食诱导的非酒精性脂肪性肝病(NAFLD)的发病有关,但关于 LPS 和 TLR4 在 NAFLD 进展过程中的变化知之甚少。益生菌能够抑制有害细菌的增殖,改善胃肠道屏障功能。然而,目前尚不清楚 LPS/TLR4 是否参与了益生菌对 NAFLD 的保护作用。在本研究中,我们描述了 NAFLD 进展过程中肠道微生物群落结构的特征,还分析了这一过程中肠道微生物群落与 LPS/TLR4 之间的关系。此外,我们应用益生菌干预来研究益生菌对肠道菌群结构、肠道完整性、血清 LPS、肝脏 TLR4 和肝脏病理的影响。我们的结果表明,在 NAFLD 进展过程中,血清 LPS 和肝脏 TLR4 显著升高,而肠道菌群多样性和肠道微生物定植抵抗力(B/E)下降。此外,益生菌可以改善肠道菌群结构和肝脏病理。益生菌还可以下调血清 LPS 和肝脏 TLR4。我们的结果表明,肠道菌群改变和内毒素血症可能都参与了 NAFLD 的进展。益生菌可能通过 LPS/TLR4 信号通路延缓 NAFLD 的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/00ef569fc63f/srep45176-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/7f02308a4ce7/srep45176-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/a69a6656ba76/srep45176-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/e0d41dde4c9d/srep45176-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/79a1dd0336cb/srep45176-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/c2a1d3a73663/srep45176-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/e44ab6daacbf/srep45176-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/7a46e23338d5/srep45176-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/8a999fe7696e/srep45176-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/00ef569fc63f/srep45176-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/7f02308a4ce7/srep45176-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/a69a6656ba76/srep45176-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/e0d41dde4c9d/srep45176-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/79a1dd0336cb/srep45176-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/c2a1d3a73663/srep45176-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/e44ab6daacbf/srep45176-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/7a46e23338d5/srep45176-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/8a999fe7696e/srep45176-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/00ef569fc63f/srep45176-f9.jpg

相似文献

1
Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.益生菌可能通过恢复肠道微生物群落结构和改善肠道内毒素血症来延缓非酒精性脂肪性肝病的进展。
Sci Rep. 2017 Mar 28;7:45176. doi: 10.1038/srep45176.
2
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.槲皮素对高脂饮食诱导的小鼠非酒精性脂肪性肝病的保护作用是通过调节肠道微生物群失衡和相关肠-肝轴激活来介导的。
Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.
3
Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.植物乳杆菌 NA136 通过调节肠道微生物群、改善肠道屏障完整性和减轻炎症来改善非酒精性脂肪性肝病。
Appl Microbiol Biotechnol. 2020 Jun;104(12):5273-5282. doi: 10.1007/s00253-020-10633-9. Epub 2020 Apr 26.
4
Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression.微生物干预作为治疗非酒精性脂肪性肝病进展的新靶点。
Cell Physiol Biochem. 2018;51(5):2123-2135. doi: 10.1159/000495830. Epub 2018 Dec 6.
5
Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?非酒精性脂肪性肝病:是好是坏,归咎于肠道微生物群?
JPEN J Parenter Enteral Nutr. 2013 Nov;37(6):787-93. doi: 10.1177/0148607113481623. Epub 2013 Mar 28.
6
Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.肠道微生物群和Toll样受体在非酒精性脂肪性肝病中的作用。
World J Gastroenterol. 2014 Jun 21;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381.
7
Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.肠-肝轴与益生菌:它们在非酒精性脂肪性肝病中的作用
World J Gastroenterol. 2014 Nov 14;20(42):15518-31. doi: 10.3748/wjg.v20.i42.15518.
8
Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease.肠道微生物群中产内毒素菌过度生长引发非酒精性脂肪性肝病。
mBio. 2020 Feb 4;11(1):e03263-19. doi: 10.1128/mBio.03263-19.
9
Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.肠-肝轴、营养与非酒精性脂肪性肝病。
Clin Biochem. 2015 Sep;48(13-14):923-30. doi: 10.1016/j.clinbiochem.2015.06.023. Epub 2015 Jul 4.
10
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?益生菌在非酒精性脂肪性肝病中的作用:肠道微生物组是否重要?
Nutrients. 2019 Nov 19;11(11):2837. doi: 10.3390/nu11112837.

引用本文的文献

1
Intestinal flora of hepatitis C after direct antiviral drug therapy: A review.直接抗病毒药物治疗后丙型肝炎的肠道菌群:综述
Medicine (Baltimore). 2025 Aug 1;104(31):e42301. doi: 10.1097/MD.0000000000042301.
2
The Role of Probiotics, Prebiotics, Synbiotics, and Postbiotics in Livestock and Poultry Gut Health: A Review.益生菌、益生元、合生元和后生元在畜禽肠道健康中的作用:综述
Metabolites. 2025 Jul 15;15(7):478. doi: 10.3390/metabo15070478.
3
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.

本文引用的文献

1
Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.系统评价:微生物失调与非酒精性脂肪性肝病。
Aliment Pharmacol Ther. 2015 Nov;42(9):1051-63. doi: 10.1111/apt.13376. Epub 2015 Aug 24.
2
The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.非酒精性脂肪性肝病之谜:从非酒精性脂肪肝到非酒精性脂肪性肝炎的进展
J Clin Exp Hepatol. 2015 Jun;5(2):147-58. doi: 10.1016/j.jceh.2015.02.002. Epub 2015 Feb 16.
3
Metabolic endotoxemia with obesity: Is it real and is it relevant?
非酒精性脂肪性肝病中的肠道微生物群:病理生理学、诊断与治疗
World J Hepatol. 2025 Jun 27;17(6):106849. doi: 10.4254/wjh.v17.i6.106849.
4
Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome.隐匿于脂肪之中:解析代谢功能障碍相关脂肪性肝病与代谢综合征之间的代谢探戈
Int J Mol Sci. 2025 Apr 7;26(7):3448. doi: 10.3390/ijms26073448.
5
The Protective Effect of FZU501 Against Alcohol-Induced Liver Injury in Mice via Gut Microbiota-Liver Axis.FZU501通过肠道微生物群-肝脏轴对小鼠酒精性肝损伤的保护作用
Foods. 2025 Mar 19;14(6):1054. doi: 10.3390/foods14061054.
6
Gut microbiota differences, metabolite changes, and disease intervention during metabolic - dysfunction - related fatty liver progression.代谢功能障碍相关脂肪性肝病进展过程中的肠道微生物群差异、代谢物变化及疾病干预
World J Hepatol. 2025 Mar 27;17(3):103854. doi: 10.4254/wjh.v17.i3.103854.
7
Correlation between differences in the intestinal flora structure and Chinese medicine evidence in patients with Wilson disease-related liver fibrosis analyzed via high-throughput sequencing technology.基于高通量测序技术分析肝豆状核变性相关肝纤维化患者肠道菌群结构差异与中医证候的相关性
Biosci Microbiota Food Health. 2025;44(2):146-159. doi: 10.12938/bmfh.2024-081. Epub 2024 Dec 11.
8
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.非酒精性脂肪性肝病炎症管理的治疗靶点与方法
Biomedicines. 2025 Feb 6;13(2):393. doi: 10.3390/biomedicines13020393.
9
Probiotic intervention and exercise mitigate inflammation and histopathological alterations in the liver of wistar rats on a high-fat diet.益生菌干预和运动可减轻高脂饮食的Wistar大鼠肝脏中的炎症和组织病理学改变。
Mol Biol Rep. 2025 Feb 9;52(1):215. doi: 10.1007/s11033-025-10320-w.
10
sp. for the Attenuation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice.用于减轻小鼠代谢功能障碍相关脂肪性肝病的物种。
Microorganisms. 2024 Dec 3;12(12):2488. doi: 10.3390/microorganisms12122488.
肥胖与代谢性内毒素血症:它是真实存在的且相关吗?
Biochimie. 2016 May;124:11-20. doi: 10.1016/j.biochi.2015.06.020. Epub 2015 Jun 29.
4
Gut Microbiota: Association with NAFLD and Metabolic Disturbances.肠道微生物群:与非酒精性脂肪性肝病及代谢紊乱的关联
Biomed Res Int. 2015;2015:979515. doi: 10.1155/2015/979515. Epub 2015 May 19.
5
Non-alcoholic fatty liver disease in 2015.2015年的非酒精性脂肪性肝病
World J Hepatol. 2015 Jun 18;7(11):1450-9. doi: 10.4254/wjh.v7.i11.1450.
6
Inflammasome activation and function in liver disease.炎症小体的激活及其在肝脏疾病中的作用。
Nat Rev Gastroenterol Hepatol. 2015 Jul;12(7):387-400. doi: 10.1038/nrgastro.2015.94. Epub 2015 Jun 9.
7
Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.脂肪细胞型脂肪酸结合蛋白和肿瘤坏死因子-α在2型糖尿病合并非酒精性脂肪性肝病中的作用
Genet Mol Res. 2015 Apr 10;14(2):2940-6. doi: 10.4238/2015.April.10.1.
8
Remifentanil Ameliorates Liver Ischemia-Reperfusion Injury Through Inhibition of Interleukin-18 Signaling.瑞芬太尼通过抑制白细胞介素-18信号通路减轻肝脏缺血再灌注损伤。
Transplantation. 2015 Oct;99(10):2109-17. doi: 10.1097/TP.0000000000000737.
9
A concise review of non-alcoholic fatty liver disease.非酒精性脂肪性肝病简述。
Atherosclerosis. 2015 Mar;239(1):192-202. doi: 10.1016/j.atherosclerosis.2015.01.001. Epub 2015 Jan 13.
10
Common features of the metabolic syndrome and nonalcoholic fatty liver disease.代谢综合征和非酒精性脂肪性肝病的共同特征。
Rev Recent Clin Trials. 2014;9(3):148-58. doi: 10.2174/1574887109666141216103908.